This article discusses the India prophylaxis study discussed here, with this news story.
Dramatically, a two-dose Ivermectin was associated with a 73% reduction in COVID-19 infections over a month period. This study used a dose of 300 μg/kg given twice.
Iraqi Study Support Ivermectin as a COVID-19 Treatment
A group of researchers from Iraq from Alkharkh General Directorate of Health, Alkharkh Hospital, Alforat Hospital and Alnahrain University collaborated for the second new study, “Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, ” looks at Ivermectin as a treatment for those ill with COVID-19. In the study 70 COVID-19 patients, 48 mild-moderate, 11 severe, and 11 in critical care, were looked at. The participants in the treatment arm got 200ug/kg PO of Ivermectin for two-three days and doxycycline twice a day for five-ten days. The control arm of the study also included 70 patients, this time 48 mild-moderate, 22 severe, and zero critical care patients.
Severe Patients Had 0% Mortality Rate
Time to recovery, disease progression, and mortality rates were the “outcome assessing parameters. ” The results showed that in the Ivermectin/Doxycycline group, three of 70 progressed to more advanced disease. And out of 11 severe cases, one got worse. In the control group, seven of 70 got sicker and also seven out of the 22 severe cases got worse. The treatment group showed mortality of 0/48 for mild-moderate cases, 0/11 for the severe cases, and 2/11 for critical care cases. In the control group 6 of the 22 severe cases ended in death. In their conclusions, the authors note that the Ivermectin doxycycline combo both reduced recovery time and reduced the proportion of patient who went on to more advanced disease. Mortality for severe patients was 22. 72% for the control group and 0% for the treatment group. But, 18. 2% of critically ill patients in the study group did die. So, the implication is that the earlier treatment is begun, “the higher rate of successful therapy. ”
The concluding (bold) sentence is kind of lame. It's not that ivermectin works best in the early stages. As ICON showed, it works for very sick patients too; ICON found that ivermectin produced a 52% reduction in fatalities for those who are sick enough to require O2 supplementation. The 18.2% reflects the fact that critically ill patients are likely to die. IIRC, 38% of ICON 02-supplemented patients died with ivermectin. We can guess that considerably more critical patients would have died without ivermectin -- but it's just a guess because there weren't any critical patients in the control arm, for ethical reasons.
I think the conclusion "IVM works best if administered as early as possible" is pretty consistent over all articles and statements by researchers and doctors. Marik, Alam, Carvalho, Borody have all stressed that IVM should be given very early to kill the virus and avoid cytokine storm.
Perhaps we could agree on the conclusion that chances of survival for those that developed late pulmonary/inflammatory stage (per Marik's lecture) would have been much better if treated with IVM in the early stage rather than in the late stage.
[-] TrumpLyftAlles | 1 points | Nov 07 2020 22:37:30
This article discusses the India prophylaxis study discussed here, with this news story.
Dramatically, a two-dose Ivermectin was associated with a 73% reduction in COVID-19 infections over a month period. This study used a dose of 300 μg/kg given twice.
And the Iraqi IVM + DOXY trial:
Iraqi Study Support Ivermectin as a COVID-19 Treatment
A group of researchers from Iraq from Alkharkh General Directorate of Health, Alkharkh Hospital, Alforat Hospital and Alnahrain University collaborated for the second new study, “Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, ” looks at Ivermectin as a treatment for those ill with COVID-19. In the study 70 COVID-19 patients, 48 mild-moderate, 11 severe, and 11 in critical care, were looked at. The participants in the treatment arm got 200ug/kg PO of Ivermectin for two-three days and doxycycline twice a day for five-ten days. The control arm of the study also included 70 patients, this time 48 mild-moderate, 22 severe, and zero critical care patients.
Severe Patients Had 0% Mortality Rate
Time to recovery, disease progression, and mortality rates were the “outcome assessing parameters. ” The results showed that in the Ivermectin/Doxycycline group, three of 70 progressed to more advanced disease. And out of 11 severe cases, one got worse. In the control group, seven of 70 got sicker and also seven out of the 22 severe cases got worse. The treatment group showed mortality of 0/48 for mild-moderate cases, 0/11 for the severe cases, and 2/11 for critical care cases. In the control group 6 of the 22 severe cases ended in death. In their conclusions, the authors note that the Ivermectin doxycycline combo both reduced recovery time and reduced the proportion of patient who went on to more advanced disease. Mortality for severe patients was 22. 72% for the control group and 0% for the treatment group. But, 18. 2% of critically ill patients in the study group did die. So, the implication is that the earlier treatment is begun, “the higher rate of successful therapy. ”
The concluding (bold) sentence is kind of lame. It's not that ivermectin works best in the early stages. As ICON showed, it works for very sick patients too; ICON found that ivermectin produced a 52% reduction in fatalities for those who are sick enough to require O2 supplementation. The 18.2% reflects the fact that critically ill patients are likely to die. IIRC, 38% of ICON 02-supplemented patients died with ivermectin. We can guess that considerably more critical patients would have died without ivermectin -- but it's just a guess because there weren't any critical patients in the control arm, for ethical reasons.
permalink
[-] massimaux | 2 points | Nov 08 2020 00:09:07
I think the conclusion "IVM works best if administered as early as possible" is pretty consistent over all articles and statements by researchers and doctors. Marik, Alam, Carvalho, Borody have all stressed that IVM should be given very early to kill the virus and avoid cytokine storm.
Perhaps we could agree on the conclusion that chances of survival for those that developed late pulmonary/inflammatory stage (per Marik's lecture) would have been much better if treated with IVM in the early stage rather than in the late stage.
permalink